MBX Biosciences, Inc. (MBX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. Thanks for joining us today. We have a session with Microbix to discuss the Q2 results they put out this morning. You can find those on the company's website on CDAR and the press release probably was sent to your inbox, let's hope. So with me today, I've got Ken Hughes, COO, Jim Curry, CFO, and Cameron Groom, CEO. The format of the session will be a review of the quarterly results by Cameron and his team, and then we'll open it up for Q&A. So feel free to start putting your questions in the Q&A box if you'd like, or you can email them to me. I don't believe that we're going to work off a formal presentation today. But as always, this session will contain forward-looking statements. You can find more about those on the company's website, on the presentation on the website, which I will update later today with the results. And with that out of the way, I'd like to turn the mic over to Cameron Groom, CEO. Hi, Cameron. Hello, Debra. I'll start by taking myself off mute. It's always a good start for these things. Thank you very much, Debra. and Jim and Ken for joining us and for Second Deborah as well. And thank you to everyone participating for taking the time this morning. Very pleased to be reporting our results for the second quarter and first half of Microbics' fiscal 2025. In these periods, the three and six months respectively, we've demonstrated solid sales excellent gross margins and material net earnings. All those achieved as we've been continuing to build out the capabilities and capacity needed to successfully engage with the largest multinational diagnostics companies and PTEQA agencies and clinical lab chains. Our Q2 results specifically, we had $5.3 million in total revenues. Strengths in our antigen or in Greek test ingredients sa...